Fiche publication
Date publication
août 2025
Journal
Neurology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DE SEZE Jérôme
Tous les auteurs :
Robin C, Rollot F, Lefort M, Casey R, Vukusic S, Mathey G, Ciron J, De Seze J, Stankoff B, Maillart E, Ruet A, Labauge PM, Kwiatkowski A, Zephir H, Papeix C, Defer G, Lebrun-Frenay C, Moreau T, Laplaud DA, Berger E, Clavelou P, Thouvenot E, Heinzlef O, Pelletier J, Casez O, Bourre B, Wahab A, Magy L, Moulin S, Camdessanche JP, Doghri I, Sarov M, Hankiewicz K, Pottier C, Dos Santos A, Manchon E, Tchikviladze M, Nifle C, Kerbrat A, Edan G, Le Page E, Michel L,
Lien Pubmed
Résumé
The therapeutic strategy in patients with late-onset MS (LOMS) remains poorly defined. In this study, we aimed to evaluate both clinical and MRI outcomes between 2 cohorts of patients with relapsing-remitting LOMS treated or not yet treated.
Mots clés
Humans, Male, Female, Middle Aged, Disease Progression, Multiple Sclerosis, Relapsing-Remitting, drug therapy, Age of Onset, Magnetic Resonance Imaging, Adult, Treatment Outcome, Follow-Up Studies, Recurrence, Cohort Studies, Aged
Référence
Neurology. 2025 08 12;105(3):e213744
